• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Organon & Co. (NY: OGN )

    15.03 -0.28 (-1.83%)
    Official Closing Price Updated: 7:00 PM EST, Nov 15, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Organon & Co.

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment
    Organon & Co (NYSE: OGN)  
    Via Benzinga
    Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
    From Organon & Co.
    Via Business Wire
    Healthy Pharma Favorites
    Here's a look at two drug makers that we recommend in our Growth & Income Portfolio. The stocks in this portfolio are generally higher-quality, larger-cap companies that have fallen out of favor. 
    Via Talk Markets
    AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
    Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
    Via Benzinga
    Merck Spinoff Organon Beats Quarterly Views, But Offers Dim Guidance
    Organon's sales and earnings fell less than expected, but 2022 sales guidance missed. 
    Via Investor's Business Daily
    Earnings Scheduled For February 17, 2022
    Companies Reporting Before The Bell • Palantir Technologies (NYSE:PLTR) is estimated to report quarterly earnings at $0.04 per share on revenue of $417.69 million. 
    Via Benzinga
    Overview Of Value Stocks In The Healthcare Sector
    What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
    Via Benzinga
    World Markets News For Thursday
    Ericsson stock lost another 5.27% today in US markets. 
    Via Talk Markets
    Established Brands Hit Organon's Q4 Sales, Expects FY22 Sales Of Upto $6.4B
    Organon & Co's (NYSE: OGN) Q4 FY21 sales decreased 1% to $1.6 billion, beating the consensus of $1.57 billion. Women's Health increased 6%, driven primarily... 
    Via Benzinga
    Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2021
    From Organon & Co.
    Via Business Wire
    Organon Acquires Contraceptive Products, Marvelon® and Mercilon®, in the People’s Republic of China, including Hong Kong and Macau, and Agrees to Acquire these Products in Vietnam
    From Organon & Co.
    Via Business Wire
    Nuclear Winter
    Mexico is raising interest rates to 6%, from 5.5%. 
    Via Talk Markets
    Organon antaa koko henkilökunnalleen vapaapäivän oman terveytensä edistämiseksi kansainvälisenä naisten päivänä
    ”Koska Covid-19-pandemialla on edelleen suhteettoman suuri vaikutus naisiin, Organon kutsuu muita organisaatioita liittymään joukkoonsa ja olemaan 
    Via EIN Presswire
    Organon Declares Paid Time Off for All Employees on International Women’s Day; Employees to Focus on Their Own Health in Recognition of Growing Women’s Health Inequity
    From Organon & Co.
    Via Business Wire
    Organon To Report Fourth Quarter and Full Year Results and Host Conference Call on February 17, 2022
    From Organon & Co.
    Via Business Wire
    FDA Accepts Samsung Bioepis’ and Organon’s sBLA for their Citrate-Free, High-Concentration HUMIRA® (Adalimumab) Biosimilar Candidate
    From Organon & Co.
    Via Business Wire
    Organon To Present at the 40th Annual J.P. Morgan Healthcare Virtual Conference
    From Organon & Co.
    Via Business Wire
    Organon Completes Acquisition of Forendo Pharma
    From Organon & Co.
    Via Business Wire
    Warren Buffett Is Selling These Stocks
    Looking to make money moves like Warren Buffett? Want to know which stocks Buffett is selling? Interested in finding out why these stock sales might be a huge mistake? 
    Via Talk Markets
    Tuesday Markets Coverage
    GE was up on hopes for cheaper oil. But most stocks were down on oil price hike fears. 
    Via Talk Markets
    Novartis May Have Buyer(s) For Its Sandoz Unit - Report
    According to a German newspaper, Swedish-based investment group EQT and the Struengmann family of Germany are considering a joint move to purchase the Novartis AG... 
    Via Benzinga
    Organon To Present at the Evercore ISI 4th Annual HealthCONx Conference
    From Organon & Co.
    Via Business Wire
    3 Recent Spin-Off Stocks Worth A Spot in Your Portfolio
    Spin-off stocks can be lucrative for shareholders in both legacy businesses and recently created public companies. Here are three to know. 
    Via InvestorPlace
    Berkshire Exited Merck Before COVID Pill Boost; Trimmed Holdings In AbbVie, Bristol Myers In Q3
    Warren Buffett's Berkshire Hathaway Inc (NYSE: BRK-A) cleared its stake in Merck & Co Inc (NYSE: MRK) in Q3, right on the eve of a significant stock... 
    Via Benzinga
    Warren Buffet Takes A Stake In Royalty Pharma And Exits Merck — What You Need To Know
    Warren Buffet's Berkshire Hathaway added more than 13 million shares. 
    Via Investor's Business Daily
    Johnson & Johnson Pops As It Announces The Biggest Split In Health Care
    Johnson & Johnson will split its consumer health unit into a publicly traded company. 
    Via Investor's Business Daily
    Veteran's Day
    Stock markets took a tumble today across the board, but not as far down as at the opening. 
    Via Talk Markets
    Lower Sales Impact Organon's Q3 Margins; Acquires Forendo Pharma For Over $900M
    Organon & Co (NYSE: OGN) has reported Q3 sales of $1.6 billion, down 1% Y/Y, slightly higher than the consensus of $1.58 billion. Women's Health declined... 
    Via Benzinga
    Organon Beat Quarterly Forecasts, Unveiled Takeover — Here's Why Shares Fell
    Organon topped forecasts on Thursday and announced its plan to buy Forendo Pharma. 
    Via Investor's Business Daily
    Organon Reports Results for the Third Quarter Ended September 30, 2021
    From Organon & Co.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.